VG Life Sciences (OTC Pink: VGLS), has received approval from the Institutional Review Board of the University of Texas Health Science Center San Antonio to expand the types of cancers being studied in the Company’s ongoing physician-initiated Phase 1 clinical trial. The IRB action allows the study to immediately broaden scope to the treatment of all solid tumors, which includes a wide and diverse range of cancer types including breast, colon, lung, liver and pancreas cancer. Effective immediately, principal investigator Dr. Tyler Curiel will begin screening patients with all solid tumors to study the safety of hydroxychloroquine (HCQ) in combination with sorafenib (marketed as Nexevar™ by Bayer AG). VG Life Sciences holds the exclusive worldwide license to the body of patents underlying the use of MDT compounds in the treatment of cancers.
Concurrent with receipt of IRB approval, noted oncologist Dr. Tyler Curiel has announced that he will expand the study of HCQ into patients suffering from relapsed or refractory (drug-resistant) cancers including those of breast, colon, lung, liver and pancreas, and is now screening patients for trial eligibility at the Cancer Therapy and Research Center (CTRC) of the University of Texas Health Sciences Center San Antonio. The protocol for the trial will remain otherwise unchanged, including endpoints, dosing and follow-up evaluation.
VG Life Sciences’ Chief Scientist, Dr. Karen Newell Rogers, commented on the Company’s progress in the clinical trials arena, saying, “The initial work of Dr. Tyler Curiel utilizing this combination of VG Life Sciences’ compound and sorafenib in ovarian cancer has been very encouraging in terms of its safety. It is just what we expected and we are enthused about expanding this to other cancer types, as well.”
Dr. Tyler Curiel, the lead investigator, said, “We now have approval to use sorafenib and HCQ to treat all solid tumors. I have identified candidate patients for this expanded protocol, and we are continuing screening for potential enrollment.”
Dr. Curiel is an internationally recognized expert and speaker in tumor immunology and in the humanities, has been a featured scientist on the NOVANow Science Television program on PBS, and is the recipient of numerous medical and civic service awards including the Mauveny Prize for Cancer Research from Tulane University, the STARS Research Enhancement Award from the University of Texas and the Health Care Hero Award from the San Antonio Business Journal. Dr. Curiel holds membership in a multitude of professional organizations and sits on the Editorial Boards of several publications including The Journal of Immunology and The Journal of Clinical Investigation.
Haig Keledjian, VG Life Sciences’ CEO, said, “We are rapidly progressing through the multiple stages in the validation of our science. Broadening our safety and efficacy studies to include breast, colon, lung, liver and pancreas tumors significantly expands the markets we are working to address, and helps us move closer to bringing effective and efficient treatments, that are more comfortably tolerated, to those seeking treatment for these cancers.”
没有评论:
发表评论